Significance Statement {#s01}
======================

The focus of this study was on the occupancies of blonanserin for both dopamine D~2~ and D~3~ receptors in vivo. This study found that 12 mg blonanserin occupied D~3~-rich region (i.e., 75.7% in globus pallidus and 72.4% in substantia nigra) as much as D~2~-rich region (i.e., 74.3% in caudate and 73.3% in putamen) in healthy volunteers. Correlation analysis between the plasma concentration of blonanserin and receptor occupancy showed that the EC~50~ values of D~2~-rich regions and D~3~-rich regions are very similar (0.39 ng/mL, r=0.43 and 0.40 ng/mL, r=0.79). Our results indicated the possibility that some of the pharmacological effect of blonanserin is mediated via D~3~ receptor antagonism.

Introduction {#s5}
============

The mechanism of the antipsychotic effect of neuroleptics mainly focuses on the antagonism of D~2~ receptor ([@CIT0027]). D~2~ receptor antagonism can also induce some adverse effects (e.g., Parkinsonism, hyperprolactinemia), and therefore many researchers have been studying the effects of antipsychotics on the dopaminergic system and other monoaminergic systems, and also the association between pharmacological treatment and the change of monoaminergic systems in vivo.

Dopamine D~3~ receptor, a member of the dopamine D~2~-like receptor family, localizes in the limbic area and coexists with D~2~ receptors in the substantia nigra as well as in many other areas in human brain. D~3~ receptor has similarities to other members of the D~2~-like receptor family, but D~3~ receptor has very high affinity for dopamine and modulates dopamine release as an autoreceptor ([@CIT0011]). Some previous studies have reported that selective D~3~ receptor antagonists might increase the extracellular dopamine concentrations in the medial prefrontal cortex ([@CIT0011]) and are also able to increase acetylcholine ([@CIT0017]). These pharmacological studies and studies of rodent D~3~ receptors have suggested that blockade of D~3~ receptor might represent a new treatment mechanism for schizophrenia ([@CIT0012]).

Many atypical antipsychotics and some typical antipsychotics have high affinities for both D~2~ and D~3~ receptors ([@CIT0008]). Recent technological progress has allowed us to visualize the distribution of D~3~ receptors in vivo. \[^11^C\]-(+)-PHNO is a D~3~/D~2~ agonist radioligand for positron emission tomography (PET) with preferential in vivo selectivity for dopamine D~3~ over D~2~ receptor ([@CIT0033]; [@CIT0006]). Almost all of the signal of \[^11^C\]-(+)-PHNO in both caudate and putamen represented D~2~ receptor sites, while up to 100% of the signal in substantia nigra, 67% in globus pallidus, and 26% in ventral striatum represented D~3~ receptor sites ([@CIT0026]). An in vitro affinity study suggested that antipsychotics would occupy D~3~ receptors as much as D~2~ receptors, although antipsychotics reportedly occupied D~3~ receptors moderately less than D~2~ receptors ([@CIT0008]), and a PET study with \[^11^C\]-(+)-PHNO reported that antipsychotics (i.e., clozapine, risperidone, olanzapine) did not decrease or even increased the in vivo nondisplaceable binding potential (BP~ND~) of D~3~ receptors in human brain ([@CIT0009]). Another study also reported that chronically administered antipsychotics (i.e., clozapine, olanzapine, and haloperidol) showed lower selectivity for D~3~ compared with D~2~ receptors ex vivo than in vitro in rat brain ([@CIT0018]).

Blonanserin is an atypical antipsychotic, but unlike other atypical antipsychotics, the binding affinity for D~2~ receptors (Ki=0.284 nM) is slightly higher than that for 5-HT~2A~ receptors (Ki=0.64 nM) in vitro ([@CIT0020]). Blonanserin has high in vitro affinity for dopamine D~3~ receptor (Ki=0.277 nM), similar to that for D~2~ receptor (Ki=0.284 nM) (Baba et al., 2008). Blonanserin occupied a D~3~-rich region (i.e., cerebellum lobe 9--10) similarly to a D~2~-rich region (i.e., striatum) in rat brain, while risperidone, olanzapine, and aripiprazole did not (Baba et al., 2008). Blonanserin demonstrated efficacy against cognitive impairment induced by phencyclidine by inhibiting both dopamine D~3~ and serotonin 5-HT~2A~ receptors in rat ([@CIT0013]). Thus, blonanserin has been thought to have D~3~ antagonism identical to D~2~ and clinical efficacy by D~3~ receptors. However, there has been no study of the evaluation of D~3~ occupancy by blonanserin.

In this study, we investigated whether a clinical dose of blonanserin occupies D~3~ receptors as well as D~2~ receptors in healthy subjects.

Methods {#s6}
=======

Subjects {#s7}
--------

Six healthy male volunteers (range 27--46 years; mean±SD, 35.7±7.6) were enrolled. None had a history of present or past psychiatric, neurological, or somatic disorders, or alcohol or substance-related problems. After thorough explanation of the study, written informed consent was obtained from all participants. This study was approved by the review board of Nippon Medical School Hospital, Tokyo, Japan.

Study Design {#s8}
------------

This study was designed as a single administration, open-label protocol. Each subject underwent 2 PET scans, the first prior to taking blonanserin, and the second 2 hours after being administered of 12 mg blonanserin, which targeted the time-to-maximum blood concentration of blonanserin ([@CIT0023]).

PET Procedures {#s9}
--------------

PET scans were carried out with Eminence SET-3000GCT-X (Shimadzu Corp) to measure regional brain radioactivity. This scanner provides 99 sections with an axial field of view of 26.0 cm. Spatial resolution was 3.45 mm in-plane and 3.72 mm axially full-width at half-maximum. A head fixation device was used during the scans. A 15-min transmission scan was done to correct for attenuation using a ^137^Cs source. Dynamic PET scan was performed for 90 min (1 min×15, 5 min×15) after i.v. bolus injection of \[^11^C\]-(+)-PHNO. Injected radioactivity was 196.4 to 385.0 MBq (348.8±64.2 (mean±SD MBq) for drug-free condition; 339.8±70.2 MBq for blonanserin condition). The injected mass of \[^11^C\]-(+)-PHNO was 1.9 -- 2.5 μg (2.2±0.3 μg for drug-free condition; 2.4±0.1 μg for blonanserin condition). Specific radioactivity was 41.7 -- 95.4 GBq/µmol (77.7±7.5 GBq/µmol for drug-free condition; 77.9±7.5 GBq/µmol for blonanserin condition) at the time of injection.

MRI Procedures {#s10}
--------------

Magnetic resonance (MR) images of the brain were acquired with 1.5T MR imaging, Intera 1.5T Achieve Nova (Philips Medical Systems) as proton density image (echo time=17 msec; repetition time=6000 msec; field of view=22 cm, 2-dimensional, 256×256; slice thickness=2 mm; number of excitations=2). These images were used for analysis of the PET scans.

Measurement of Plasma Concentration of Blonanserin {#s11}
--------------------------------------------------

Venous blood samples were taken just before second PET scans (2 hours after taking 12 mg blonanserin), collected in tubes containing EDTA-2Na, and centrifuged at 3000 rpm for 10 min at 4ºC. Separated plasma samples were stored at -80ºC until analysis. Plasma concentration was measured by validated method using high-performance liquid chromatography-tandem mass spectrometry with a target lower quantification limit of 0.001 ng/mL (Sekisui Medical Co., Ltd.).

Data Analysis {#s12}
-------------

MR images were co-registered to summated PET images with the mutual information algorithm using PMOD (version 3.4; PMOD Technologies Ltd). Regions of interest (ROIs) were defined for the caudate, putamen, ventral striatum, globus pallidus, and substantia nigra, and were drawn manually in accordance with Tziortzi's study ([@CIT0032]). We defined the caudate and putamen as D~2~-rich regions and the substantia nigra and globus pallidus as D~3~-rich regions, according to Searle's study ([@CIT0026]). ROIs were drawn manually on overlaid summated PET and co-registered MR images of each subject. By matching the targeted frame to the average of the first 10 frames (i.e., 0--10 minutes), motion corrections were conducted in 3 scans of 2 subjects because of head movements.

Quantitative estimate of binding of \[^11^C\]-(+)-PHNO was performed using a simplified reference tissue model (Lammertsma and Hume, 1996), with the cerebellar cortex as reference region. This model has been validated to reliably estimate BP~ND~, which compares the concentration of radioligand in the receptor-rich region with the receptor-free region ([@CIT0015]), for \[^11^C\]-(+)-PHNO ([@CIT0006]).

Receptor occupancy by drugs was calculated by the following equation:

$$\text{Occupancy~}\left( \% \right)\  = \ \left( {\text{BP}_{\text{NDbase}} - \text{BP}_{\text{NDdrug}}} \right)\ /\text{~BP}_{\text{NDbase}} \times \text{~1}00,$$

where occupancy is the receptor occupancy, BP~NDbase~ is BP~ND~ under drug-free condition, and BP~NDdrug~ is BP~ND~ under blonanserin condition.

We used a 1-site binding model, the same as a previous study ([@CIT0010]). The relationship between plasma concentration and receptor occupancy was shown by the following equation:

$$\text{Occupancy~}\left( \% \right)\  = \text{~E}_{\text{max}} \times \text{~C~}/\ (\text{EC}_{\text{5}0}＋\text{C})\  \times \text{~1}00,$$

where C is the plasma concentration of drug, E~max~ is the maximum occupancy, and EC~50~ is the plasma concentration required to achieve 50% occupancy ([@CIT0029]; [@CIT0010]). E~max~ was fixed at 1 and EC~50~ \>0, the same as in previous occupancy studies ([@CIT0029]; [@CIT0010]). Since discrepancy of D~3~ receptor occupancy between in vitro and in vivo studies has been reported ([@CIT0010]; [@CIT0018]), correlations between plasma concentration and receptor occupancy were examined.

Results {#s13}
=======

Five subjects each completed two 90-min PET scans with \[^11^C\]-(+)-PHNO. One subject provided partial data: the first PET scan (drug-free condition) was stopped at 70 min because of the subject's anxiety. We then included both conditions of 0 to 70 min PET data of this subject.

[Figure 1](#F1){ref-type="fig"} shows BP~ND~ of each ROI in each condition. Average BP~ND~ in drug-free condition was as follows: caudate (BP~ND~ range 1.04--1.68; mean±SD, 1.53±0.24), putamen (BP~ND~ range 1.28--2.06; 1.82±0.29), ventral striatum (BP~ND~ range 1.59--2.85; 2.40±0.43), globus pallidus (BP~ND~ range 1.56--2.68; 2.16±0.40), and substantia nigra (BP~ND~ range 0.96--1.42; 1.06±0.17). Average BP~ND~ in blonanserin condition was as follows: caudate (BP~ND~ range 0.27--0.60; 0.40±0.12), putamen (BP~ND~ range 0.20--0.77; 0.50±0.19), ventral striatum (BP~ND~ range 0.19--1.70; 0.99±0.52), globus pallidus (BP~ND~ range 0.19--0.91; 0.54±0.24), and substantia nigra (BP~ND~ range 0.11--0.47; 0.30±0.13). The average level of receptor occupancy by a single dose of blonanserin 12 mg was as follows: caudate (range 64.3--81.5; 74.3±5.6%), putamen (range 60.4--84.3; 73.3±8.2%), ventral striatum (range 40.1--88.2; 60.8±17.1%), globus pallidus (range 65.8--87.6; 75.7±8.6%), and substantia nigra (range 56.0--88.7; 72.4±11.0%) ([Table 1](#T1){ref-type="table"}).

![Binding potential (BP~ND~) of \[^11^C\]-(+)-PHNO for every region of interest before and after taking 12 mg blonanserin. Filled circles represent the subject with 70-min PET scans.](pyy00401){#F1}

###### 

Average Binding Potential and Occupancy of Dopamine Receptors in Each Region

  Region of Interest   Drug-free   Blonanserin   Occupancy (%)
  -------------------- ----------- ------------- ---------------
  Caudate              1.53±0.24   0.40±0.12     74.3±5.6
  Putamen              1.82±0.29   0.50±0.20     73.3±8.2
  Globus pallidus      2.16±0.40   0.54±0.24     75.7±8.6
  Ventral striatum     2.40±0.43   0.99±0.52     60.8±17.1
  Substantia nigra     1.06±0.17   0.30±0.13     72.4±11.0

The average drug concentration of blonanserin was 1.49±0.88 (mean±SD) ng/mL (range 0.58--2.90). Correlations between plasma concentration of blonanserin and receptor occupancy in D~2~-rich and D~3~-rich ROI are shown in [Figure 2](#F2){ref-type="fig"}. EC~50~ was 0.39 ng/mL (df=11, r=0.43) for D~2~-rich region and 0.40 ng/mL (df=11, r=0.79) for D~3~-rich region.

![Correlation between receptor occupancy in D~2~-rich (caudate and putamen) and D~3~-rich (globus pallidus and substantia nigra) regions with \[^11^C\]-(+)-PHNO and plasma concentration of 12 mg blonanserin. Filled circles represent the subject with 70-min PET scans.](pyy00402){#F2}

Discussion {#s14}
==========

In this study, we examined the receptor occupancies in both D~2~-rich and D~3~-rich regions by a single dose of 12 mg blonanserin using \[^11^C\]-(+)-PHNO PET. A single dose of 12 mg blonanserin occupied dopamine receptors in D~3~-rich regions (i.e., substantia nigra, globus pallidus) as much as in D~2~-rich regions (i.e., caudate, putamen). Receptor occupancy in the striatum by 12 mg blonanserin (74.3% for caudate and 73.3% for putamen) was almost the same as by \[^11^C\]raclopride (68.5% for the striatum as calculated based on our previous data; [@CIT0030]). Thus, a single dose of 12 mg blonanserin, within the clinical daily dose range for the treatment of schizophrenia, occupied D~3~ receptors to approximately the same extent as D~2~ receptors. Thus, this is the first study to show that this dopamine antagonist occupied both D~2~ and D~3~ receptors at about the same levels.

Since dopaminergic hypofunction in the prefrontal cortex has been implicated in the pathogenesis of negative symptoms ([@CIT0004]) and cognitive dysfunctions of schizophrenia ([@CIT0024]), D~3~ receptor antagonism might improve the negative symptoms and cognitive deficits of schizophrenia. Animal studies have reported that blonanserin showed cognitive efficacy via D~3~ receptor antagonism and that it had a beneficial effect on prefrontal dopamine transmission ([@CIT0012]; [@CIT0021]; [@CIT0013]). Other clinical studies showed that blonanserin induced improvements in verbal fluency and executive function ([@CIT0031]; [@CIT0014]), which might be related to the effect of this antipsychotic on dopamine transmission prefrontal cortex function. It has also been reported that functional connectivity between the prefrontal cortex and salience/executive control networks negatively associated with midbrain D~3~ receptor availability (Cole et al., 2011). Many PET studies have suggested that around 70% to 80% D~2~ receptor occupancy in the striatum is required for an antipsychotic effect with a lower risk of extrapyramidal adverse effects ([@CIT0005]; [@CIT0022]; [@CIT0016]). Previous studies showed that 150 mg of ABT-925, a selective D~3~ receptor antagonist, possibly improves positive and negative symptoms of schizophrenia, and that it occupied about 30% of D~3~ receptors in substantia nigra and globus pallidus ([@CIT0010]; [@CIT0002]). A recent study showed that a clinical dose of cariprazine, a D~3~-preferring dual D~3~/D~2~ receptor partial agonist for the treatment of schizophrenia, occupied at least 76% of D~3~ receptors, along with 45% of D~2~ receptors ([@CIT0007]). However, the adequate degree of D~3~ receptor occupancy for an antipsychotic effect or improvement of motivation and/or cognition has been unclear. Our result provided evidence that a single dose of 12 mg blonanserin antagonizes D~3~ receptor as much as D~2~ receptor, as has been indicated by previous studies ([@CIT0001]), and therefore further study regarding what percentage of D~3~ occupancy by antipsychotics might improve cognition could be beneficial for treatment strategies of schizophrenia.

The mechanism underlying the discrepancies between in vitro and in vivo bindings of several antipsychotics to dopamine D~3~ receptors ([@CIT0010]; [@CIT0018]) is still unclear. However, several explanations have been proposed. Girgis presented the upregulation scenario ([@CIT0008]). The study in baboons demonstrated binding of both D~2~ and D~3~ receptors by an acute dose of haloperidol (haloperidol: 70% of putamen and 61% of globus pallidus, clozapine: 43% of putamen and 21% of globus pallidus). Girgis further suggested that upregulation of D~3~ receptor induced by chronic use of antipsychotics might affect the discrepancy between the results of in vitro affinity study and in vivo PET study ([@CIT0008]). Our study participants were healthy volunteers with a single administration, and our result was consistent with this scenario. Another explanation could be the influence of endogenous dopamine. Schotte reported that the D~2~/D~3~ potency ratios of antipsychotics (i.e., clozapine, olanzapine, risperidone, haloperidol) in vivo were 2 to 10 times higher than those of in vitro competitive binding experiments ([@CIT0025]), and they suggested that this effect was due to the in vivo inhibitory influence of endogenous dopamine. It has been suggested that antipsychotics inhibit D~2~ and D~3~ receptors in a dose-dependent manner, but the relationship between drug concentration and inhibitory effect differed according to the respective antipsychotics. Tadori reported that most antipsychotics at clinical dose sufficiently antagonize D~2~ receptor signals but not D~3~ receptor signals, while blonanserin, haloperidol, and fluphenazine inhibit D~3~ receptor at a similar level to D~2~ receptor ([@CIT0028]). Their study suggested that a clinical dose of antipsychotics, except for blonanserin, haloperidol, and fluphenazine, preferentially inhibits D~2~ receptor compared with D~3~ receptor in vivo ([@CIT0028]).

There are several limitations to this study. First, we performed PET scan after only a single administration of an antipsychotic in 6 healthy subjects. It has been reported that chronic use of antipsychotics increases D~3~ receptors among patients with schizophrenia ([@CIT0009]). Another study of drug-naïve patients with schizophrenia showed that 2.5 weeks of antipsychotic treatment doubled BP~ND~ of D~3~ receptors ([@CIT0019]). These studies indicated that the density of D~3~ receptors in patients treated with antipsychotics might be different from that in healthy controls. Thus, to evaluate the precise relationship between drug concentration and both D~2~ and D~3~ receptor occupancies, further study with larger sample size, including patients, will be needed. Second, 1 of our 6 subjects provided only 70-min data from the PET scan. It was considered that this might affect the evaluation of BP~ND~. However, the relationship between occupancy of receptors and drug concentration was almost unchanged when excluding this subject (in caudate: r = 1.00, EC~50~ =0.38; in putamen: r=0.77, EC~50~=0.42; in ventral striatum: r=0.62, EC~50~=0.82; in globus pallidus: r=0.79, EC~50~=0.38; in substantia nigra: r=0.85, EC~50~=0.46).

In conclusion, our study using \[^11^C\]-(+)-PHNO demonstrated that a single dose of 12 mg blonanserin could occupy D~3~ receptors to the same degree as D~2~ receptors in vivo. Our results indicated the possibility that some of the pharmacological effect of blonanserin was mediated via D~3~ receptor antagonism.
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